PT - JOURNAL ARTICLE AU - Guo, Rui AU - Meng, Hongping AU - Li, Biao TI - <strong>Can pre-treatment <sup>18</sup>F-FDG PET/CT predict prognosis of extranodal natural killer/T-cell lymphoma?</strong> DP - 2020 May 01 TA - Journal of Nuclear Medicine PG - 173--173 VI - 61 IP - supplement 1 4099 - http://jnm.snmjournals.org/content/61/supplement_1/173.short 4100 - http://jnm.snmjournals.org/content/61/supplement_1/173.full SO - J Nucl Med2020 May 01; 61 AB - 173Objectives: The utility of pre-treatment 18F-FDG PET/CT in staging of patients with extranodal natural killer/T-cell lymphoma (ENKTL) has been established in recent years, but the role of it in predicting the prognosis of ENKTL is still inconclusive. Therefore, we evaluated the prediction value of pre-treatment 18F-FDG PET/CT in ENKTL.Methods: This is a prospective study, 60 consecutive patients with newly diagnosed ENKTL underwent 18F-FDG PET/CT scan before therapy. Forty-two patients received combination of chemotherapy and radiotherapy, 18 patients received chemotherapy alone. We recorded maximum standardized uptake value (SUVmax), mean SUV (SUVmean), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) of the tumor and the following parameters of each patient, including gender, age, stage, nasal lymphoma infiltration range, extranasal lymphoma infiltration, lymph node involvement, bone marrow involvement and several clinical parameters. Survival curves were obtained using Kaplan-Meier analysis and compared using log rank test, followed by multivariate analysis using Cox proportional hazards model to assess the independent effects of these parameters on overall survival (OS) and progression-free survival (PFS) of ENKTL.Results: Survival analysis found that the following parameters were predictive for 2-y OS: MTV (P &lt; 0.001), TLG (P &lt; 0.001), Ann Arbor staging based on PET/CT (P &lt; 0.001), extranasal lymphoma infiltration (P = 0.006), lymph node involvement (P = 0.031) and bone marrow involvement on PET/CT (P &lt; 0.001). SUVmax (P = 0.653), SUVmean (P = 0.446) and nasal lymphoma infiltration range (P = 0.308) have no value for 2-y OS. The following parameters were predictive for 2-y PFS: MTV (P = 0.001), TLG (P = 0.009), Ann Arbor staging based on PET/CT (P &lt; 0.001), extranasal lymphoma infiltration (P &lt; 0.001) and bone marrow involvement on PET/CT (P &lt; 0.001). SUVmax (P = 0.274), SUVmean (P = 0.213), nasal lymphoma infiltration range (P = 0.621) and lymph node involvement (P = 0.069) have no value for 2-y PFS. Clinical parameters, such as B symptom (P = 0.021) was predictive for 2-y OS, but not for 2-y PFS (P = 0.149). Eastern Cooperative Oncology Group (ECOG) score (P = 0.004) was predictive for 2-y PFS, but not for 2-y OS (P = 0.521). Multivariate analysis showed bone marrow involvement and Ann Arbor staging based on PET/CT to be the significant independent prognostic factor of both OS (P = 0.046 and 0.019, respectively) and PFS (P = 0.033 and 0.015, respectively). Conclusions: Our study demonstrated that bone marrow involvement and Ann Arbor staging based on 18F-FDG PET/CT to be the significant independent prognostic factor of both OS and PFS.